Presentation matters: Buffers, packaging, and delivery devices for new, oral enteric vaccines for infants.
Oral administration of vaccines is simpler and more acceptable than injection via needle and syringe, particularly for infants (Fig. 1) This route is promising for new vaccines in development against enterotoxigenic Escherichia coli (ETEC) and Shigella that cause childhood diarrhea with devastating consequences in low-resource countries. However, vaccine antigens and adjuvants given orally need buffering against the degradative effects of low stomach pH, and the type and volume of antacid buffer require special attention for infants. In addition, container/closure systems must be compatible with vaccine formulations, protect against water and gas transfer, and have minimal impact on the cold chain. Health care workers in demanding low-resource settings need an administration device that is easy to use, yet will accurately measure and safely deliver the correct vaccine dose. Developers must consider manufacturing capabilities, and immunization program managers want affordable vaccines. As new combination enteric vaccine candidates advance into clinical evaluation, features of the final vaccine presentation-liquid or dry format, diluent, buffer, primary and secondary packaging, and administration device-should be taken into account early in product development to achieve the greatest possible impact for the vaccine.
a PATH , Seattle , WA , USA.
Manjari
M
Lal
a PATH , Seattle , WA , USA.
Courtney
C
Jarrahian
D000284:Administration, Oral; D004339:Drug Compounding; D022361:Escherichia coli Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D022281:Shigella Vaccines / Q000008:administration & dosage* / Q000276:immunology*
D022361:Escherichia coli Vaccines; D022281:Shigella Vaccines
buffers; developing countries; diarrheal disease; enteric pathogens; immunization; oral delivery; packaging; vaccine presentation